Novo Nordisk's next-gen weight loss drug outperforms Zepbound in new trial
Source: The Hill
Novo Nordisk says its potential Wegovy successor helped patients lose more weight than Zepbound in a major clinical trial.
This is aggregated or syndicated coverage. Reporting and media belong to the original publisher.
Read the original source at The Hill